GlassScriptPhysician profile
Johanna Lee
NPI 1245962869
$8,726.73
in general payments reported to CMS, 2019-2025
55 companies · $1,858 in 2025
The $1,858 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $197 · 2023: $4,807 · 2024: $1,864 · 2025: $1,858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,360 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,360.40 |
| Education | $168.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $3,003.59 | 2023 | Cabometyx |
| E.R. Squibb & Sons, L.L.C. | $384.31 | 2023-2025 | Opdivo, Opdualag |
| Incyte Corporation | $320.96 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Astrazeneca Pharmaceuticals LP | $301.10 | 2023-2025 | Enhertu, Lynparza, Imfinzi |
| Janssen Biotech, INC. | $293.39 | 2024-2025 | Akeega, Balversa, Erleada |
| Abbvie INC. | $249.03 | 2022-2025 | |
| Pfizer INC. | $233.57 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $226.20 | 2024-2025 | Onivyde |
| Novartis Pharmaceuticals Corporation | $222.98 | 2023-2025 | |
| Seagen INC. | $217.16 | 2022-2023 | Padcev, Tukysa, Adcetris |
| Genzyme Corporation | $215.11 | 2023-2025 | |
| Spectrum Pharmaceuticals INC. | $209.46 | 2023 | Rolvedon |
| Merck Sharp & Dohme LLC | $205.55 | 2023-2025 | Keytruda, Lynparza |
| Eisai INC. | $172.80 | 2023-2025 | |
| Genentech USA, INC. | $165.95 | 2023-2025 | Phesgo, Tecentriq, Perjeta |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $163.17 | 2023-2025 | Libtayo |
| Glaxosmithkline, LLC. | $160.39 | 2023-2025 | Ojjaara, Blenrep |
| Sobi, INC | $153.76 | 2023-2024 | |
| Deciphera Pharmaceuticals INC. | $141.14 | 2023-2025 | Qinlock, Romvimza |
| Tersera Therapeutics LLC | $123.02 | 2023-2025 | Zoladex |
| Astellas Pharma US INC | $96.55 | 2024-2025 | Padcev, Xospata, Vyloy |
| Stemline Therapeutics INC. | $95.16 | 2023-2024 | Orserdu |
| Springworks Therapeutics, INC. | $89.78 | 2024-2025 | Ogsiveo |
| Takeda Pharmaceuticals U.S.A., INC. | $86.01 | 2023-2025 | Ninlaro, Hyqvia, Fruzaqla |
| Daiichi Sankyo INC. | $84.55 | 2024-2025 | Enhertu, Datroway |
| Kyowa Kirin, INC. | $78.53 | 2022-2025 | Poteligeo |
| Acrotech Biopharma INC. | $77.85 | 2023-2025 | Beleodaq |
| Jazz Pharmaceuticals INC. | $70.30 | 2023-2025 | |
| Gilead Sciences, INC. | $69.99 | 2023 | Trodelvy |
| Amgen INC. | $58.85 | 2023 | Blincyto, Kyprolis, Xgeva |
| Servier Pharmaceuticals LLC | $56.32 | 2024-2025 | |
| Octapharma USA, INC. | $53.39 | 2023-2024 | Panzyga, Octagam Immune Globulin (Human) |
| Mirati Therapeutics, INC. | $49.99 | 2024 | Krazati |
| Lilly USA, LLC | $46.28 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Emd Serono, INC. | $44.38 | 2023-2024 | Bavencio |
| Alexion Pharmaceuticals, INC. | $43.69 | 2023-2025 | Ultomiris |
| Morphosys, US INC. | $38.65 | 2023 | Monjuvi |
| Aveo Pharmaceuticals, INC. | $29.95 | 2025 | |
| Beigene USA, INC. | $28.72 | 2024 | Brukinsa |
| Syndax Pharmaceuticals, INC. | $28.28 | 2025 | |
| Verity Pharmaceuticals INC. | $28.15 | 2024 | Trelstar |
| Pharmaessentia USA Corporation | $27.57 | 2024 | Besremi |
| Taiho Oncology, INC. | $27.55 | 2024 | |
| Genmab U.S., INC. | $26.16 | 2025 | Epkinly |
| Adc Therapeutics America, INC. | $24.75 | 2024 | |
| Apellis Pharmaceuticals, INC. | $24.65 | 2024 | Empaveli |
| Kite Pharma, INC. | $24.11 | 2023 | |
| Sun Pharmaceutical Industries INC. | $24.00 | 2024 | |
| Array Biopharma INC | $23.80 | 2024 | Lorbrena, Mektovi, Braftovi |
| Celgene Corporation | $21.95 | 2023 | Reblozyl |
| Agios Pharmaceuticals, INC. | $21.71 | 2025 | Pyrukynd |
| Oyster Point Pharma, INC. | $17.07 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.27 | 2023 | |
| Pharmacyclics LLC, An Abbvie Company | $15.45 | 2023 | Imbruvica |
| Menarini Silicon Biosystems, INC. | $13.68 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johanna Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.